MetLife Investment Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

MetLife Investment Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,170	Closed	-$97K	–	2564
2021 Q3	$97K	Buy	+2,170	New	+$106K	﹤0.01%	2453
2021 Q2	–	Sell	-1,785	Closed	-$134K	–	2498
2021 Q1	$134K	Buy	1,785 +56	+3%	+$5.82K	﹤0.01%	2221
2020 Q4	$188K	Hold	1,729	–	–	﹤0.01%	2017
2020 Q3	$153K	Hold	1,729	–	–	﹤0.01%	2016
2020 Q2	$184K	Hold	1,729	–	–	﹤0.01%	1960
2020 Q1	$103K	Buy	+1,729	New	+$117K	﹤0.01%	2069
2019 Q4	–	Sell	-1,837	Closed	-$191K	–	2334
2019 Q3	$191K	Hold	1,837	–	–	﹤0.01%	1979
2019 Q2	$170K	Buy	+1,837	New	+$128K	﹤0.01%	2133
2018 Q4	–	Sell	-1,311	Closed	-$156K	–	2600
2018 Q3	$156K	Hold	1,311	–	–	﹤0.01%	2225
2018 Q2	$134K	Buy	+1,311	New	+$162K	﹤0.01%	2115

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MetLife Investment Management's SYRS Position: Q4 2021 in Review

MetLife Investment Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 2,170 shares — an estimated $97K sold.

MetLife Investment Management first reported a position in SYRS in Q2 2018 and held it in 10 quarters. The position peaked at $191K in Q3 2019. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

MetLife Investment Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
MetLife Investment Management sold 2,170 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $97K.
MetLife Investment Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
MetLife Investment Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $191K in Q3 2019.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.